CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 47.93 USD -2.06% Market Closed
Market Cap: 4.1B USD
Have any thoughts about
CRISPR Therapeutics AG?
Write Note

Intrinsic Value

The intrinsic value of one CRSP stock under the Base Case scenario is hidden USD. Compared to the current market price of 47.93 USD, CRISPR Therapeutics AG is hidden .

The Intrinsic Value is calculated as the average of DCF and Relative values:

CRSP Intrinsic Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Backtest
CRISPR Therapeutics AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CRSP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CRSP?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Intrinsic Value and Risks & Rewards hidden

Sign up to unlock intrinsic valuation and risk & rewards analysis.

Sign Up
Company Quality
HIDDEN
Show
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about CRISPR Therapeutics AG

Provide an overview of the primary business activities
of CRISPR Therapeutics AG.

What unique competitive advantages
does CRISPR Therapeutics AG hold over its rivals?

What risks and challenges
does CRISPR Therapeutics AG face in the near future?

Has there been any significant insider trading activity
in CRISPR Therapeutics AG recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CRISPR Therapeutics AG.

Provide P/S
for CRISPR Therapeutics AG.

Provide P/E
for CRISPR Therapeutics AG.

Provide P/OCF
for CRISPR Therapeutics AG.

Provide P/FCFE
for CRISPR Therapeutics AG.

Provide P/B
for CRISPR Therapeutics AG.

Provide EV/S
for CRISPR Therapeutics AG.

Provide EV/GP
for CRISPR Therapeutics AG.

Provide EV/EBITDA
for CRISPR Therapeutics AG.

Provide EV/EBIT
for CRISPR Therapeutics AG.

Provide EV/OCF
for CRISPR Therapeutics AG.

Provide EV/FCFF
for CRISPR Therapeutics AG.

Provide EV/IC
for CRISPR Therapeutics AG.

Show me price targets
for CRISPR Therapeutics AG made by professional analysts.

What are the Revenue projections
for CRISPR Therapeutics AG?

How accurate were the past Revenue estimates
for CRISPR Therapeutics AG?

What are the Net Income projections
for CRISPR Therapeutics AG?

How accurate were the past Net Income estimates
for CRISPR Therapeutics AG?

What are the EPS projections
for CRISPR Therapeutics AG?

How accurate were the past EPS estimates
for CRISPR Therapeutics AG?

What are the EBIT projections
for CRISPR Therapeutics AG?

How accurate were the past EBIT estimates
for CRISPR Therapeutics AG?

Compare the revenue forecasts
for CRISPR Therapeutics AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CRISPR Therapeutics AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CRISPR Therapeutics AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of CRISPR Therapeutics AG compared to its peers.

Compare the P/E ratios
of CRISPR Therapeutics AG against its peers.

Discuss the investment returns and shareholder value creation
comparing CRISPR Therapeutics AG with its peers.

Analyze the financial leverage
of CRISPR Therapeutics AG compared to its main competitors.

Show all profitability ratios
for CRISPR Therapeutics AG.

Provide ROE
for CRISPR Therapeutics AG.

Provide ROA
for CRISPR Therapeutics AG.

Provide ROIC
for CRISPR Therapeutics AG.

Provide ROCE
for CRISPR Therapeutics AG.

Provide Gross Margin
for CRISPR Therapeutics AG.

Provide Operating Margin
for CRISPR Therapeutics AG.

Provide Net Margin
for CRISPR Therapeutics AG.

Provide FCF Margin
for CRISPR Therapeutics AG.

Show all solvency ratios
for CRISPR Therapeutics AG.

Provide D/E Ratio
for CRISPR Therapeutics AG.

Provide D/A Ratio
for CRISPR Therapeutics AG.

Provide Interest Coverage Ratio
for CRISPR Therapeutics AG.

Provide Altman Z-Score Ratio
for CRISPR Therapeutics AG.

Provide Quick Ratio
for CRISPR Therapeutics AG.

Provide Current Ratio
for CRISPR Therapeutics AG.

Provide Cash Ratio
for CRISPR Therapeutics AG.

What is the historical Revenue growth
over the last 5 years for CRISPR Therapeutics AG?

What is the historical Net Income growth
over the last 5 years for CRISPR Therapeutics AG?

What is the current Free Cash Flow
of CRISPR Therapeutics AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for CRISPR Therapeutics AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CRISPR Therapeutics AG

Current Assets 2B
Cash & Short-Term Investments 2B
Other Current Assets 8.8m
Non-Current Assets 329.4m
Long-Term Investments 11.2m
PP&E 291.6m
Other Non-Current Assets 26.7m
Current Liabilities 127.8m
Accounts Payable 9.5m
Accrued Liabilities 108.3m
Other Current Liabilities 10m
Non-Current Liabilities 231.1m
Other Non-Current Liabilities 231.1m
Efficiency

Earnings Waterfall
CRISPR Therapeutics AG

Revenue
202.2m USD
Operating Expenses
-556.9m USD
Operating Income
-354.7m USD
Other Expenses
88.8m USD
Net Income
-265.9m USD

Free Cash Flow Analysis
CRISPR Therapeutics AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CRSP Profitability Score
Profitability Due Diligence

CRISPR Therapeutics AG's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
Declining ROE
Declining ROIC
hidden
Profitability
Score

CRISPR Therapeutics AG's profitability score is hidden . The higher the profitability score, the more profitable the company is.

CRSP Solvency Score
Solvency Due Diligence

CRISPR Therapeutics AG's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
hidden
Solvency
Score

CRISPR Therapeutics AG's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 82.54 USD with a low forecast of 30.3 USD and a high forecast of 208.95 USD.

Lowest
Price Target
30.3 USD
37% Downside
Average
Price Target
82.54 USD
72% Upside
Highest
Price Target
208.95 USD
336% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CRSP?

Click here to dive deeper.

Dividends

CRISPR Therapeutics AG
does not pay dividends
Shareholder Yield

Current shareholder yield for CRSP is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Show
Dividend Yield
No dividends
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Ownership

CRSP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

CRSP News

Other Videos

Profile

CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG

Country

Switzerland

Industry

Biotechnology

Market Cap

4.1B USD

Dividend Yield

0%

Description

CRISPR Therapeutics AG operates as a gene editing company. The company is headquartered in Zug, Zug and currently employs 473 full-time employees. The company focuses on the development of transformative gene-based medicines for serious diseases. The firm develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The firm has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The firm has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Contact

ZUG
Zug
Baarerstrasse 14
+41415613277.0
www.crisprtx.com

IPO

-

Employees

473

Officers

See Also

Discover More
What is the Intrinsic Value of one CRSP stock?

The intrinsic value of one CRSP stock under the Base Case scenario is hidden USD.

Is CRSP stock undervalued or overvalued?

Compared to the current market price of 47.93 USD, CRISPR Therapeutics AG is hidden .

Back to Top